|
Sex (male/female)
|
50/28
|
|
Age (years)
|
70 (20–87)
|
|
APACHE II score
|
24 (3–38)
|
|
SOFA score
|
11 (0–19)
|
|
MAP before the PMX treatment (mmHg)
|
64 (40–104)
|
|
CVP before the PMX treatment (mmHg)
|
15 (12–22)
|
|
Creatinine before the PMX treatment (mg/dl)
|
1.42 (0.41–10.24)
|
|
Endotoxin level before the PMX treatment (pg/mL)
|
11.3 (0.8–1925)
|
|
Lactate level before the PMX treatment (mmol/L)
|
3.7 (1.0–23.0)
|
|
Patients with diabetes mellitus
|
24
|
|
Patients received corticosteroid therapy
|
13
|
|
The times of PMX therapy
|
1 (1–6)
|
|
Total PMX treatment time (min)
|
1456 (80–18,100)
|
|
Suspected causative microorganisms
|
|
GNR
|
41
|
|
GPC
|
12
|
|
GPR
|
2
|
|
Unknown origin
|
23
|
|
Infection site
|
|
Abdomen
|
27
|
|
Bloodstream
|
15
|
|
Lung
|
10
|
|
Urinary tract
|
6
|
|
Others (unknown origin)
|
20
|
